April 8, 2020 -- MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second CRISPR patent granted to the company in the U.S. and its 23rd CRISPR-related patent worldwide.
This places MilliporeSigma as the only provider with a patent for the fusion of chromatin-modulating peptides to CRISPR proteins. The ability to fuse chromatin, which often blocks DNA, with CRISPR-chrom technology improves efficiency of the gene-editing process, according to the company. The initial work on the technology was published in the CRISPR Journal in late February.
MilliporeSigma's full CRISPR patent portfolio includes CRISPR-related technologies covering foundational intellectual property and alternative genome-editing methods.